July 27, 2007
'Prescribing by Numbers: Drugs and the Definition of Disease'
In October 1957, a top executive from Pfizer had some cautionary words at an annual meeting of U.S. drug manufacturers. In a sense, the industry had performed too well. Antibiotics had been so successful, they had effectively limited their own potential market. Something new was needed for long-term growth. The industry found that potential in a "logic of risk reduction," says Jeremy A. Greene, a fellow in the department of social medicine at Harvard Medical School and a resident at Brigham
This is an article for subscribers only. You may access this article by purchasing a:
Digital or Print Subscription
Web Pass
Already have an account? Log In Now.
-
Faculty
-
First Person
-
The Chronicle Review
